Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

668 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.
Ng SWK, Murphy T, King I, Zhang T, Mah M, Lu Z, Stickle N, Ibrahimova N, Arruda A, Mitchell A, Mai M, He R, Madala BS, Viswanatha DS, Dick JE, Chan S, Virtanen C, Minden MD, Mercer T, Stockley T, Wang JCY. Ng SWK, et al. Among authors: king i. Blood Adv. 2022 Feb 8;6(3):1064-1073. doi: 10.1182/bloodadvances.2021005741. Blood Adv. 2022. PMID: 34872104 Free PMC article.
The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
Kim DDH, Novitzky Basso I, Kim TS, Yi SY, Kim KH, Murphy T, Chan S, Minden M, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Ng SWK, Stockley T, Zhang T, King I, Mattsson J, Wang JCY. Kim DDH, et al. Among authors: king i. EJHaem. 2022 May 23;3(3):873-884. doi: 10.1002/jha2.466. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051057 Free PMC article.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S. Madariaga A, et al. Among authors: king i. Nat Commun. 2023 Mar 15;14(1):1452. doi: 10.1038/s41467-023-37084-w. Nat Commun. 2023. PMID: 36922497 Free PMC article. Clinical Trial.
Clinical reporting for personalized cancer genomics requires extensive access to subscription-only literature.
D'Souza S, Downs G, Hendrikx S, Fazelzad R, Boldt G, Burns K, Chapman D, Dawes D, Giannarakos A, Oja LA, Schorr R, Babb M, Hodgson A, McEwan J, Jacobs P, Stockley T, Tripp T, King I. D'Souza S, et al. Among authors: king i. J Med Libr Assoc. 2023 Apr 21;111(1-2):579-590. doi: 10.5195/jmla.2023.1572. J Med Libr Assoc. 2023. PMID: 37312803 Free PMC article.
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A. Kelly D, et al. Among authors: king i. Cancers (Basel). 2021 Jul 20;13(14):3640. doi: 10.3390/cancers13143640. Cancers (Basel). 2021. PMID: 34298857 Free PMC article.
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A. Rose AAN, et al. Among authors: king i. J Immunother Cancer. 2021 Jan;9(1):e001642. doi: 10.1136/jitc-2020-001642. J Immunother Cancer. 2021. PMID: 33483342 Free PMC article.
Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices.
Rao S, Pitel B, Wagner AH, Boca SM, McCoy M, King I, Gupta S, Park BH, Warner JL, Chen J, Rogan PK, Chakravarty D, Griffith M, Griffith OL, Madhavan S. Rao S, et al. Among authors: king i. JCO Clin Cancer Inform. 2020 Jul;4:602-613. doi: 10.1200/CCI.19.00169. JCO Clin Cancer Inform. 2020. PMID: 32644817 Free PMC article. Review.
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Horak P, et al. Among authors: king i. Genet Med. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29. Genet Med. 2022. PMID: 35101336 Free PMC article.
668 results